New director of German HTA body
This article was originally published in SRA
Executive Summary
Germany's health technology appraisal institute, IQWiG, has elected Professor Jürgen Windeler as its new director. The chief physician and deputy managing director of the MDS (Essen) – the medical advisory board for statutory health insurers and long term care insurance – does not appear to be the soft option for the pharmaceutical industry that some had predicted1.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.